Compound Summary
Compound Information
Salirasib
Compound Name: | Salirasib |
Compound CID: | 5469318 |
Synonyms: | Salirasib 162520-00-5 Farnesylthiosalicylic acid S-Farnesylthiosalicylic acid Farnesyl Thiosalicylic Acid More... |
Iupac Name: | 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid |
InChI: | InChI=1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+ |
InChIKey: | WUILNKCFCLNXOK-CFBAGHHKSA-N |
Canonical Smiles: | CC(=CCCC(=CCCC(=CCSC1=CC=CC=C1C(=O)O)C)C)C |
Isomeric Smiles: | CC(=CCC/C(=C/CC/C(=C/CSC1=CC=CC=C1C(=O)O)/C)/C)C |
Molecular Weight: | 358.5 |
Molecular Formula: | C22H30O2S |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Salirasib
Molecular Weight: | 358.5 |
Molecular Formula: | C22H30O2S |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 3 |
Rotatable Bond Count: | 10 |
Heavy Atom Count: | 25 |
Complexity: | 498 |
Synonyms
Salirasib
| Salirasib | Salirasib |
|---|---|
Salirasib |
162520-00-5 |
Farnesylthiosalicylic acid |
S-Farnesylthiosalicylic acid |
Farnesyl Thiosalicylic Acid |
UNII-MZH0OM550M |
MZH0OM550M |
CHEMBL23293 |
2-(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylsulfanylbenzoic acid |
2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid |
2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)benzoic acid |
2-(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-ylthiobenzoic Acid |
Salirasib USAN:INN |
Farnesylthiosalicyclic acid |
Salirasib; FTS |
S-trans,trans-farnesylthiosalicylic acid |
Salirasib (INN/USAN) |
Lopac-F-8175 |
Lopac0_000517 |
MLS006010835 |
GTPL6281 |
Salirasib, >=98% (HPLC) |
CHEBI:177460 |
AMY39921 |
BCP27978 |
EX-A1170 |
ONO-7056 |
trans,trans-Farnesylthiobenzoic acid |
ZINC1650377 |
2030AH |
BDBM50034278 |
KD-032 |
MFCD00467723 |
NSC685986 |
NSC755771 |
s7684 |
2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid |
AKOS024458453 |
Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)- |
CCG-204607 |
CS-0681 |
DB12681 |
NSC-685986 |
NSC-755771 |
Benzoic acid, 2-(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-ylthio- |
NCGC00015448-01 |
NCGC00015448-02 |
NCGC00015448-03 |
NCGC00015448-11 |
NCGC00093912-01 |
NCGC00093912-02 |
AS-73028 |
HY-14754 |
SMR004701762 |
EU-0100517 |
D08995 |
F 8175 |
Farnesylthiosalicylic acid, >98% (HPLC), solid |
A882836 |
SR-01000075885 |
J-009946 |
SR-01000075885-1 |
Q27088685 |
2-(3,7,11-Trimethyl-2,6,10-dodecatrienyl)thiobenzoic acid |
2-(3,7,11-trimethyldodeca-2,6,10-trienylsulfanyl)benzoic acid |
2-((2E,6E)-3,7,11-Trimethyl-dodeca-2,6,10-trienylsulfanyl)-benzoic acid |
2-(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylsulanylbenzoic acid |
2-{(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ylsulfanyl}benzoic acid |
166445-40-5 |
Experimental Data
Salirasib
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | -17 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
Salirasib
Statistics Data
Salirasib
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -17 | 1 | 1 |
Statistics Data Visualization
Salirasib
